Isatuximab SC

DRUG2 trials

Sponsors

Sanofi, Massachusetts General Hospital

Conditions

Plasma Cell Myeloma RecurrentRelapsed Refractory Multiple MyelomaRelapsed Refractory Multiple Myeloma (RRMM)

Phase 2

ELISA in Relapsed/Refractory MM

RecruitingNCT06832865

Massachusetts General HospitalRelapsed Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM)

Start: 2025-08-14End: 2028-12-01Target: 30Updated: 2026-03-12

Phase 3

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Active, not recruitingNCT05405166

SanofiPlasma Cell Myeloma Recurrent

Start: 2022-06-23End: 2027-03-23Updated: 2025-11-14

Related Papers

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood2025-11-03

Isatuximab subcutaneous in relapsed/refractory multiple myeloma: Exposure-response and serum m-protein dynamics analyses from phase 3 iraklia Study and the phase 1b Study

Blood2025-11-03

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood2025-11-03

Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study

Blood2025-11-03

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Journal of Clinical Oncology2025-06-033 citations

Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.

Journal of Clinical Oncology2025-05-28

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Blood2022-11-159 citations